Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Baxter
McKesson
Express Scripts
Merck

Last Updated: February 3, 2023

CLINICAL TRIALS PROFILE FOR VALTREX


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Valtrex

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00005663 ↗ A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients Unknown status Glaxo Wellcome Phase 3 1999-06-01 The purpose of this study is to see if valacyclovir (Valtrex) is a safe and effective treatment for ano-genital HSV infections (herpes simplex virus infections of the anus and external genitals) in HIV-infected patients.
NCT00038831 ↗ Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS Completed M.D. Anderson Cancer Center Phase 1/Phase 2 2001-05-01 The goal of this clinical research study is to find the highest safe dose of Mylotarg that can be combined with chemotherapy in patients receiving allogeneic bone marrow transplantation. Researchers will study the effects of this treatment combination on patients with high-risk acute leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome. Primary Objective: 1. To determine the safety and maximum tolerated dose of Mylotarg as part of a reduced-intensity preparative regimen patients undergoing related, mismatched-related or matched unrelated donor transplantation. Secondary Objectives: 1. To evaluate response rates, engraftment kinetics and degree of chimerism achievable with this strategy. 2. To evaluate the incidence and severity of GVHD in this population 3. To evaluate disease-free and overall survival and relapse rates.
NCT00059592 ↗ Valacyclovir in Immunocompromised Children Completed Texas Children's Hospital Phase 1 1998-04-07 Shingles is an infection commonly seen in children with a weakened immune system (immunocompromised children). The immune system can be weakened as a result of medications that patients receive for cancer or other serious illness or as a result of a bone marrow transplantation. Shingles in children with a weakened immune system may spread throughout the body and in some instances may be life-threatening. Acyclovir is a medication that is routinely used to treat immunocompromised children with shingles in order to prevent further spread of their shingles and to help them heal faster. Acyclovir is also given to bone marrow transplant patients to prevent reactivation of HSV infection. Valacyclovir is a new drug that is metabolized (broken down in the body) to acyclovir. Valacyclovir is given by mouth and studies done in adults have shown it to be more effective than acyclovir given by mouth. The purpose of this study is to - study the pharmacology of this drug (how the body handles this drug), - determine if oral Valacyclovir can be safely given to children with shingles, and - determine the type of side effects that occur when oral Valacyclovir is given to immunocompromised children.
NCT00059592 ↗ Valacyclovir in Immunocompromised Children Completed Baylor College of Medicine Phase 1 1998-04-07 Shingles is an infection commonly seen in children with a weakened immune system (immunocompromised children). The immune system can be weakened as a result of medications that patients receive for cancer or other serious illness or as a result of a bone marrow transplantation. Shingles in children with a weakened immune system may spread throughout the body and in some instances may be life-threatening. Acyclovir is a medication that is routinely used to treat immunocompromised children with shingles in order to prevent further spread of their shingles and to help them heal faster. Acyclovir is also given to bone marrow transplant patients to prevent reactivation of HSV infection. Valacyclovir is a new drug that is metabolized (broken down in the body) to acyclovir. Valacyclovir is given by mouth and studies done in adults have shown it to be more effective than acyclovir given by mouth. The purpose of this study is to - study the pharmacology of this drug (how the body handles this drug), - determine if oral Valacyclovir can be safely given to children with shingles, and - determine the type of side effects that occur when oral Valacyclovir is given to immunocompromised children.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Valtrex

Condition Name

Condition Name for Valtrex
Intervention Trials
Healthy 9
Herpes Simplex 6
Chronic Lymphocytic Leukemia 6
HIV Infections 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Valtrex
Intervention Trials
Herpes Simplex 10
HIV Infections 7
Leukemia, Lymphoid 7
Herpes Genitalis 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Valtrex

Trials by Country

Trials by Country for Valtrex
Location Trials
United States 150
Canada 26
India 4
Brazil 3
Argentina 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Valtrex
Location Trials
Texas 20
California 9
Washington 8
Indiana 7
Florida 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Valtrex

Clinical Trial Phase

Clinical Trial Phase for Valtrex
Clinical Trial Phase Trials
Phase 4 9
Phase 3 6
Phase 2 21
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Valtrex
Clinical Trial Phase Trials
Completed 38
Recruiting 5
Terminated 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Valtrex

Sponsor Name

Sponsor Name for Valtrex
Sponsor Trials
M.D. Anderson Cancer Center 9
GlaxoSmithKline 8
University of Washington 5
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Valtrex
Sponsor Trials
Other 41
Industry 36
NIH 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Colorcon
Merck
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.